Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Grever MR"" wg kryterium: Autor


Wyświetlanie 1-14 z 14
Tytuł :
The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant.
Autorzy :
Troussard X; Department of Haematology, CHU Caen Normandie, Caen cedex 9, France.
Grever MR; Division of Hematology, The Ohio State University, Columbus, Ohio, USA.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2021 Apr; Vol. 193 (1), pp. 11-14. Date of Electronic Publication: 2020 Dec 23.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Autorzy :
Saygin C; Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
Larkin K; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Blachly JS; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Orwick S; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Ngankeu A; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Gregory CT; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Phelps MA; Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Mani S; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Walker A; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Garzon R; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Vasu S; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Walsh KJ; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Bhatnagar B; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Klisovic RB; Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia.
Grever MR; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Marcucci G; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, California.
Byrd JC; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Blum W; Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia.
Mims AS; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Dec; Vol. 95 (12), pp. 1457-1465. Date of Electronic Publication: 2020 Sep 19.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/mortality
Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/mortality
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Disease-Free Survival ; Female ; Humans ; Idarubicin/administration & dosage ; Idarubicin/adverse effects ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Male ; Middle Aged ; Survival Rate
Czasopismo naukowe
Tytuł :
Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
Autorzy :
Hughes JH; Australian Centre for Pharmacometrics, School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Australia.
Phelps MA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.; Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Upton RN; Australian Centre for Pharmacometrics, School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Australia.
Reuter SE; School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Australia.
Gao Y; Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Byrd JC; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.; Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Grever MR; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Hofmeister CC; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Marcucci G; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Blum W; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Blum KA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Foster DJR; Australian Centre for Pharmacometrics, School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Australia.
Pokaż więcej
Źródło :
British journal of clinical pharmacology [Br J Clin Pharmacol] 2019 May; Vol. 85 (5), pp. 924-934. Date of Electronic Publication: 2019 Feb 27.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Renal Elimination*
B-Lymphocytes/*immunology
Immunologic Factors/*pharmacokinetics
Lenalidomide/*pharmacokinetics
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Administration, Oral ; Adult ; Aged ; Biological Availability ; Clinical Trials, Phase I as Topic ; Creatinine/blood ; Creatinine/metabolism ; Creatinine/urine ; Datasets as Topic ; Dose-Response Relationship, Drug ; Female ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/adverse effects ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Leukemia, Lymphocytic, Chronic, B-Cell/blood ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Leukemia, Myeloid, Acute/blood ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/immunology ; Male ; Middle Aged ; Models, Biological ; Multiple Myeloma/blood ; Multiple Myeloma/drug therapy ; Multiple Myeloma/immunology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology ; Young Adult
Czasopismo naukowe
Tytuł :
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.
Autorzy :
Stephens DM; Division of Hematology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
Ruppert AS; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.
Weirda WG; Division of Cancer Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
Jones JA; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
Woyach JA; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
Maddocks K; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
Jaglowski SM; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
Andritsos LA; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
Flynn JM; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
Grever MR; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
Lozanski G; Division of Hematopathology, Department of Pathology, Ohio State University, Columbus, Ohio.
Tam C; Division of Medicine, Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
O'Brien S; Division of Cancer Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
Keating MJ; Division of Cancer Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
Muthusamy N; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
Abruzzo LV; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
Heerema NA; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.; Division of Cytogenetics, Department of Pathology, Ohio State University, Columbus, Ohio.
Byrd JC; Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.; Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.; Division of Medicinal Chemistry, College of Pharmacy, Ohio State University, Columbus, Ohio.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2015 Nov; Vol. 90 (11), pp. 967-9. Date of Electronic Publication: 2015 Oct 12.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Study
MeSH Terms :
Base Sequence*
Chromosomes, Human, Pair 17*
Sequence Deletion*
Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell/*genetics
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Female ; Humans ; Karyotype ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Middle Aged ; Molecular Sequence Data ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Risk ; Survival Analysis
Czasopismo naukowe
Tytuł :
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Autorzy :
Maddocks K; Division of Hematology, Department of Internal Medicine, The Ohio State University, Comprehensive Cancer Center, The Ohio State University, College of Pharmacy, The Ohio State University, Ohio.
Wei L
Rozewski D
Jiang Y
Zhao Y
Adusumilli M
Pierceall WE
Doykin C
Cardone MH
Jones JA
Flynn J
Andritsos LA
Grever MR
Byrd JC
Johnson AJ
Phelps MA
Blum KA
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2015 Apr; Vol. 90 (4), pp. 327-33. Date of Electronic Publication: 2015 Feb 25.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/administration & dosage
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Flavonoids*/administration & dosage
Flavonoids*/adverse effects
Flavonoids*/therapeutic use
Piperidines*/administration & dosage
Piperidines*/adverse effects
Piperidines*/therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Thalidomide/*analogs & derivatives
Tumor Lysis Syndrome/*prevention & control
Adult ; Aged ; Apoptosis/drug effects ; Cell Proliferation/drug effects ; Cohort Studies ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Lenalidomide ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Male ; Maximum Tolerated Dose ; Middle Aged ; Recurrence ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Thalidomide/therapeutic use ; Treatment Outcome ; Tumor Lysis Syndrome/etiology ; Tumor Lysis Syndrome/pathology
Czasopismo naukowe
Tytuł :
Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.
Autorzy :
Jones JA; Division of Hematology, The Ohio State University, Columbus, Ohio.
Rupert AS
Poi M
Phelps MA
Andritsos L
Baiocchi R
Benson DM
Blum KA
Christian B
Flynn J
Penza S
Porcu P
Grever MR
Byrd JC
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2014 Jan; Vol. 89 (1), pp. 19-24. Date of Electronic Publication: 2013 Sep 30.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Flavonoids/*therapeutic use
Lymphoma, Non-Hodgkin/*drug therapy
Piperidines/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology ; Drug Administration Schedule ; Female ; Flavonoids/pharmacology ; Humans ; Lymphoma, Non-Hodgkin/diagnosis ; Male ; Maximum Tolerated Dose ; Middle Aged ; Piperidines/pharmacology ; Protein Kinase Inhibitors/pharmacology ; Recurrence ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.
Autorzy :
Jaglowski SM; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA. />Ruppert AS
Heerema NA
Bingman A
Flynn JM
Grever MR
Jones JA
Elder P
Devine SM
Byrd JC
Andritsos LA
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2012 Oct; Vol. 159 (1), pp. 82-7. Date of Electronic Publication: 2012 Jul 25.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell/*genetics
Leukemia, Lymphocytic, Chronic, B-Cell/*surgery
Stem Cell Transplantation/*methods
Transplantation Conditioning/*methods
Adult ; Aged ; Cytogenetics ; Disease-Free Survival ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Karyotype ; Male ; Middle Aged ; Prognosis ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
Autorzy :
Blum KA; Division of Hematology-Oncology, Department of Internal Medicine, The Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. />Liu Z
Lucas DM
Chen P
Xie Z
Baiocchi R
Benson DM
Devine SM
Jones J
Andritsos L
Flynn J
Plass C
Marcucci G
Chan KK
Grever MR
Byrd JC
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2010 Jul; Vol. 150 (2), pp. 189-95. Date of Electronic Publication: 2010 Apr 29.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antimetabolites, Antineoplastic/*administration & dosage
Azacitidine/*analogs & derivatives
DNA Methylation/*drug effects
Leukemia, Lymphocytic, Chronic, B-Cell/*genetics
Lymphoma, Non-Hodgkin/*genetics
Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/blood ; Antimetabolites, Antineoplastic/therapeutic use ; Antimetabolites, Antineoplastic/toxicity ; Azacitidine/administration & dosage ; Azacitidine/blood ; Azacitidine/therapeutic use ; Azacitidine/toxicity ; DNA, Neoplasm/drug effects ; Decitabine ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/blood ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Lymphoma, Non-Hodgkin/blood ; Lymphoma, Non-Hodgkin/drug therapy ; Male ; Middle Aged ; Neutropenia/chemically induced ; Thrombocytopenia/chemically induced ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
Autorzy :
Shanafelt TD; Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. />Byrd JC
LaPLant B
Zent CS
Call T
Secreto C
Grever MR
Lin TS
Kay NE
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2009 Sep; Vol. 146 (6), pp. 660-4. Date of Electronic Publication: 2009 Jul 10.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Fibroblast Growth Factors/*blood
Leukemia, Lymphocytic, Chronic, B-Cell/*blood
Thrombospondin 1/*blood
Vascular Endothelial Growth Factors/*blood
Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Agents/therapeutic use ; Combined Modality Therapy ; Cyclophosphamide/therapeutic use ; Humans ; Immunotherapy ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Pentostatin/therapeutic use ; Prognosis ; Prospective Studies ; Rituximab
Czasopismo naukowe
Tytuł :
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
Autorzy :
Johnson AJ; Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA. />Wagner AJ
Cheney CM
Smith LL
Lucas DM
Guster SK
Grever MR
Lin TS
Byrd JC
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2007 Dec; Vol. 139 (5), pp. 837-44. Date of Electronic Publication: 2007 Oct 19.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*pharmacology
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Benzoquinones/*pharmacology
Lactams, Macrocyclic/*pharmacology
Leukemia, Lymphocytic, Chronic, B-Cell/*pathology
Antibodies, Monoclonal, Murine-Derived ; Antibody-Dependent Cell Cytotoxicity/drug effects ; Cytotoxicity, Immunologic/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor/methods ; Drug Synergism ; HSP90 Heat-Shock Proteins/antagonists & inhibitors ; HSP90 Heat-Shock Proteins/metabolism ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/metabolism ; Proto-Oncogene Proteins c-akt/antagonists & inhibitors ; Proto-Oncogene Proteins c-akt/metabolism ; Rituximab ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapy.
Autorzy :
Grem JL; Clinical Oncology Program, National Cancer Institute, Bethesda, MD 20892.
King SA
Chun HG
Grever MR
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 1991 Nov; Vol. 38 (3), pp. 245-7.
Typ publikacji :
Journal Article
MeSH Terms :
Heart Diseases/*chemically induced
Pentostatin/*adverse effects
Aged ; Arrhythmias, Cardiac/chemically induced ; Chest Pain/chemically induced ; Electrocardiography ; Female ; Heart Diseases/physiopathology ; Humans ; Male ; Middle Aged ; Myocardial Infarction/chemically induced ; Pentostatin/therapeutic use
Czasopismo naukowe
Tytuł :
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group.
Autorzy :
Cheson BD; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland 20892.
Bennett JM
Rai KR
Grever MR
Kay NE
Schiffer CA
Oken MM
Keating MJ
Boldt DH
Kempin SJ
et. al.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 1988 Nov; Vol. 29 (3), pp. 152-63.
Typ publikacji :
Guideline; Journal Article; Practice Guideline
MeSH Terms :
Health Planning*
Health Planning Guidelines*
Clinical Trials as Topic/*standards
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Antineoplastic Agents/adverse effects ; Antineoplastic Agents/standards ; Drug Evaluation/standards ; Eligibility Determination/standards ; Humans ; Infections/etiology ; Leukemia, B-Cell/diagnosis ; Leukemia, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/blood ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; National Institutes of Health (U.S.) ; Neoplasm Staging ; Prognosis ; United States
Czasopismo naukowe
Tytuł :
Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukaemia in accelerated or blastic phase.
Autorzy :
Copelan EA; Ohio State University, Bone Marrow Transplant Program, Columbus 43210.
Grever MR
Kapoor N
Tutschka PJ
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 1989 Apr; Vol. 71 (4), pp. 487-91.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Marrow Transplantation*
Busulfan/*therapeutic use
Cyclophosphamide/*therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*therapy
Adolescent ; Adult ; Child ; Female ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality ; Male ; Middle Aged ; Postoperative Complications/etiology ; Remission Induction ; Risk
Czasopismo naukowe
    Wyświetlanie 1-14 z 14

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies